Behavioral Intervention and Anti-Obesity Drug Therapy / 대한내과학회지
Korean Journal of Medicine
;
: 624-628, 2013.
Artigo
em Coreano
| WPRIM
| ID: wpr-162113
ABSTRACT
Obesity is associated with a reduction in life expectancy and an increase in mortality from cardiovascular diseases, cancer, and other causes. The U.S. Preventive Service Task Force (USPSTF) recommends screening all adults for obesity. Clinicians should offer or refer patients with a body mass index of 30 kg/m2 or higher to intensive, multicomponent behavioral interventions. Behavioral interventions can lead to a moderate weight loss and improvement in blood sugar and other risk factors for cardiovascular disease. Behavioral interventions decreased the incidence of diabetes diagnosis by about 50% over 2 to 3 years. Orlistat, phentermine, diethylpropion, phendimetrazine, mazindol have been approved as anti-obesity drugs by Korea Food and Drug Administration. The U.S. Food and Drug Administration approved lorcaserin and phentermine plus topiramate combination for treatment of obesity in 2012.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Fentermina
/
United States Food and Drug Administration
/
Benzazepinas
/
Glicemia
/
Doenças Cardiovasculares
/
Redução de Peso
/
Índice de Massa Corporal
/
Programas de Rastreamento
/
Morfolinas
/
Incidência
Tipo de estudo:
Estudo de etiologia
/
Estudo de incidência
/
Estudo prognóstico
/
Fatores de risco
/
Estudo de rastreamento
Limite:
Adulto
/
Humanos
País/Região como assunto:
Ásia
Idioma:
Coreano
Revista:
Korean Journal of Medicine
Ano de publicação:
2013
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS